McArdle Disease Clinical Trial
Official title:
A Phase 1b, Open-label Study to Evaluate the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Patients With McArdle Disease (Glycogen Storage Disorder 5)
Verified date | January 2022 |
Source | Reneo Pharma Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess REN001 safety in subjects with McArdle Disease
Status | Completed |
Enrollment | 19 |
Est. completion date | October 11, 2021 |
Est. primary completion date | October 11, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subjects must give written, signed and dated informed consent - Confirmed diagnosis of McArdle Disease - Subjects must be able to remain on stable medication through the study and specifically must not commence or have changes to agents that affect metabolism such as medication for diabetes - Follow a stable dietary regimen as documented by a 3-day dietary record obtained during the screening period. Exclusion Criteria: - Documented history of ongoing rhabdomyolysis - Evidence of acute crisis from their underlying disease - Currently following or planning to start a ketogenic diet - Treatment with an investigational drug within 1 month or within 5 half-lives, whichever is longer - Have been hospitalized within the 3 months prior to screening for any major medical condition - Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator in discussion with the Medical Monitor, would make the subject inappropriate for entry into this study - Pregnant or nursing females |
Country | Name | City | State |
---|---|---|---|
Spain | Instituto de Investigación Hospital 12 de Octubre | Madrid | |
United Kingdom | National Hospital for Neurology and Neurosurgery, Queens Square | London |
Lead Sponsor | Collaborator |
---|---|
Reneo Pharma Ltd |
Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse Events | Number of participants with Adverse Events (AEs) as a measure of safety and tolerability | up to Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03945370 -
Oral Ketone Body Supplementation in Patients With McArdle Disease
|
N/A | |
Completed |
NCT04349566 -
Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases
|
||
Enrolling by invitation |
NCT03211923 -
Muscle Relaxation in Myopathies With Positive Muscle Phenomena
|
||
Completed |
NCT03112889 -
Sodium Valproate for GSDV
|
Phase 2 | |
Completed |
NCT04694547 -
Ketogenic Diet Survey in Patients With McArdle Disease (GSDV)
|
||
Completed |
NCT03843606 -
Modified Ketogenic Diet in Patients With McArdle Disease Part A
|
N/A | |
Recruiting |
NCT04929002 -
Carbon-13 Magnetic Resonance Spectroscopy in Glycogen Storage Diseases
|
||
Completed |
NCT04044508 -
Modified Ketogenic Diet in Patients With McArdle Disease Part B
|
N/A | |
Recruiting |
NCT05943678 -
Novel Metabolic Muscular Biomarkers in Pompe Disease - a Non-invasive Magnetic Resonance Exploratory Pilot Study.
|